Similar Search Results

Pharmaceutical prices under regulation : tiered co-payments and reference pricing in Germany

Herr, Annika; Suppliet, Moritz - 2012

Many countries with national health care providers and health insurances regulate the market for pharmaceuticals to … (no. of firms) suggests a significant but small negative correlation with prices. -- pharmaceuticals ; prices ; co …

Persistent link: https://www.econbiz.de/10009522774

Parallel imports and manufacturer rebates : evidence from Germany

Birg, Laura - 2019

pharmaceuticals on competition by parallel imports. First, I analyze the effect of a manufacturer rebate on competition by parallel …

Persistent link: https://www.econbiz.de/10011949028

The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany

Dintsios, C. M.; Beinhauer, I. - In: Health economics review 10 (2020) 7, pp. 1-25

Background: We analysed the impact of clinical study design for oncological pharmaceuticals on the subsequent price … Health Insurance Funds. The analysis was conducted for all oncology pharmaceuticals that underwent the early benefit …. Further analyses should be performed when more oncology pharmaceuticals have passed the early benefit assessment. …

Persistent link: https://www.econbiz.de/10012291135

Product innovation success based on cancer research in the pharmaceutical industry : co-publication networks and the effects of partners

McKelvey, Maureen D.; Rake, Bastian - In: Industry and innovation 23 (2016) 5, pp. 383-406

Persistent link: https://www.econbiz.de/10011523939

Pharmaceutical prices: the impact of the launch strategy : an analysis of German data

Böhler, Yvonne-Beatrice; Lamping, Christian; Wichardt, … - 2019

pricing system was changed in 2011 in order to tie prices more to the benefits of the pharmaceuticals. A multiple linear … regression of 187 pharmaceuticals which were assessed from 2011 to 2017 suggests that, despite the change, the manufacturers …

Persistent link: https://www.econbiz.de/10012103333

Is self-regulation sufficient? : case of the German transparency code

Buske, Kristin; Jentzsch, Stefan J.; Bechter, Clemens - In: Administrative Sciences : open access journal 6 (2016) 1/3, pp. 1-12

The German pharmaceutical industry is stepping ahead with its implementation of a new transparency disclosure code for cooperation between pharmaceutical companies and health care professionals (HCPs) and health care organisations (HCOs). In Germany, this transparency code ("Transparenzkodex")...

Persistent link: https://www.econbiz.de/10012015756